Home Health Ochsner Cancer Institute Offers New Hope Through Early Phase Trials

Ochsner Cancer Institute Offers New Hope Through Early Phase Trials

by The 100 Companies

The Precision Cancer Therapies Program at Ochsner Cancer Institute offers new hope to cancer patients who may have thought they had no options. Fewer than 3% of adult cancer patients in Louisiana enroll in clinical trials; yet enrolled patients typically experience better outcomes than those who do not participate.

Through the program, patients are given access to early phase clinical trials that allow them to receive innovative therapies years before they are available. This connects Ochsner’s clinical expertise with the world-renowned Translational Genomics Research Institute – or TGEN.

For more information on clinical trials, visit or call 504-800-6370.

Dr. Marc Matrana, Medical Director, Ochsner Precision Cancer Therapies Program

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

The New Orleans 100